Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Commerce Committee expected to release FDA reform bill by early July.

This article was originally published in The Tan Sheet

Executive Summary

HOUSE COMMERCE COMMITTEE FDA REFORM BILL EXPECTED BY EARLY JULY, using Oversight & Investigations Subcommittee ranking minority member Rep. Ron Wyden's (D-Ore.) "FDA Modernization Act" (HR 1742) as a basis for discussion. Introduced June 6, HR 1742 reflects agreement on both the left and right of the political spectrum on the need for such FDA reforms as increased use of expert panels to speed review of certain drugs; use of independent testing organizations; fewer restrictions on export of U.S.-made products; and separate requirements for approval of drugs and biologics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel